XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| XBIT | XBiotech Inc. | 2026-10-15 09:33:47 | 2.24 | 0.06 | 2.75 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XBIT | 0001626878 | XBiotech Inc. | US98400H1023 | 5299002WACAY28TQAS52 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | A1 | 5217 WINNEBAGO LANE | AUSTIN | TX | 78744 | UNITED STATES | US | 512-386-2900 | 5217 WINNEBAGO LANE, AUSTIN, TX, 78744 | 5217 WINNEBAGO LANE, AUSTIN, TX, 78744 | — | Biopharmaceutical | 2005 | Sushma Shivaswamy | — | http://xbiotech.com | 77,050,226 | 30,487,731 | 30,487,731 | XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases. | 2026-10-09 04:58:34 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 77,050,226 | -44,819,498 | -36.7766 | 30,487,731 | 0 | 0 |
| 2024 | 121,869,724 | -18,607,094 | -13.2457 | 30,487,731 | 36,850 | 0.121 |
| 2023 | 140,476,818 | 7,668,412 | 5.774 | 30,450,881 | 11,606 | 0.0381 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Angela Hu | Director | 2025 | 200,000 | 40,000 | — | — | 5,419 | 245,419 |
| Sushma Shivaswamy | Chief Executive Officer, Chief Scientific Officer | 2025 | 468,557 | 90,000 | — | — | 12,436 | 570,992 |
| John Simard | Chief Executive Officer, President | 2025 | 1,250,000 | 8,530,442 | — | — | 12,436 | 30,134,204 |
| Sushma Shivaswamy | Chief Executive Officer, Chief Scientific Officer | 2024 | 450,000 | 197,047 | — | — | 10,498 | 657,572 |
| John Simard | Chief Executive Officer, President | 2024 | 1,205,083 | 5,030,000 | — | — | 10,498 | 6,245,581 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 85 |
| 2024 | 92 |
| 2023 | 82 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | 0 |
| Cost Of Revenue | — | — | 0 |
| Gross Profit | — | — | 0 |
| Research And Development Expenses | 47,390,000 | 37,757,000 | 32,848,000 |
| General And Administrative Expenses | 8,295,000 | 4,714,000 | 4,662,000 |
| Operating Expenses | — | — | 37,510,000 |
| Operating Income | -55,685,000 | -42,471,000 | -37,510,000 |
| Net Income | -45,540,000 | -38,531,000 | -24,557,000 |
| Earnings Per Share Basic | -1.49 | -1.26 | -0.81 |
| Earnings Per Share Diluted | -1.49 | -1.26 | -0.81 |
| Weighted Average Shares Outstanding Basic | 30,487,731 | 30,460,980 | 30,438,459 |
| Weighted Average Shares Outstanding Diluted | 30,487,731 | 30,460,980 | 30,438,459 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 125,551,000 | 172,677,000 | 200,023,000 |
| Marketable Securities Current | — | — | 0 |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | 0 | 158,000 | 75,000 |
| Other Assets Current | 1,042,000 | 1,032,000 | 760,000 |
| Total Assets Current | 126,953,000 | 174,567,000 | 201,718,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 23,129,000 | 24,526,000 | 24,897,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 23,129,000 | 24,526,000 | 24,897,000 |
| Total Assets | 150,082,000 | 199,093,000 | 226,615,000 |
| Accounts Payable | 1,535,000 | 2,223,000 | 2,516,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 6,318,000 | 2,632,000 | 3,501,000 |
| Total Liabilities Current | 7,929,000 | 15,105,000 | 6,100,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 1,803,000 | 1,720,000 | 1,669,000 |
| Total Liabilities | 9,732,000 | 16,825,000 | 7,769,000 |
| Common Stock | 276,727,000 | 273,105,000 | 271,152,000 |
| Retained Earnings | -136,377,000 | -90,837,000 | -52,306,000 |
| Accumulated Other Comprehensive Income | — | — | 0 |
| Total Shareholders Equity | 140,350,000 | 182,268,000 | 218,846,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,686,000 | 1,745,000 | 1,744,000 |
| Share Based Compensation Expense | 3,622,000 | 1,753,000 | 3,262,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | -234,000 | 83,000 | -473,000 |
| Change In Other Assets | 10,000 | 271,000 | 160,000 |
| Change In Accounts Payable | -688,000 | -364,000 | 91,000 |
| Change In Other Liabilities | 3,686,000 | -877,000 | 1,895,000 |
| Cash From Operating Activities | -39,920,000 | -30,963,000 | -18,725,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 289,000 | 1,304,000 | 362,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -289,000 | -1,304,000 | 61,497,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | 200,000 | 4,800 |
| Repurchase Of Common Stock | — | 0 | 14,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -10,250,000 | 10,450,000 | -9,000 |
| Change In Cash | -47,126,000 | -27,346,000 | 42,717,000 |
| Cash At End Of Period | 125,551,000 | 172,677,000 | 200,023,000 |
| Income Taxes Paid | -81,000 | 85,000 | — |
| Interest Paid | 486,000 | 400,000 | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.49 | -1.26 | -0.81 |
| Price To Earnings Ratio | -1.604 | -3.1349 | -4.9383 |
| Earnings Growth Rate | 18.254 | 55.5556 | -25 |
| Price Earnings To Growth Ratio | -0.0879 | -0.0564 | 0.1975 |
| Book Value Per Share | 4.6035 | 5.9837 | 7.1898 |
| Price To Book Ratio | 0.5192 | 0.6601 | 0.5563 |
| Ebitda | -43,935,000 | -36,701,000 | -22,813,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 289,000 | 1,374,000 | 381,000 |
| Free Cash Flow | -40,209,000 | -32,337,000 | -19,106,000 |
| Return On Equity | -0.3245 | -0.2114 | -0.1122 |
| One Year Beta | 1.3034 | 1.1707 | 0.8413 |
| Three Year Beta | 1.1481 | 1.0041 | 0.9665 |
| Five Year Beta | 1.069 | 0.9256 | 0.9112 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Troy Tevi David | Director | 2025-10-01 | 56,000 | A | 56,000 |
| Kuendig Thomas Martin | Director | 2025-10-01 | 79,115 | A | 79,115 |
| Soffer David Spencer | Director | 2025-10-01 | 51,000 | A | 51,000 |
| Rademaker Craig Evan | Director | 2025-10-01 | 92,104 | A | 92,104 |
| SIMARD JOHN | Director, Chief Executive Officer, 10% owner | 2025-03-17 | 1,026,228 | A | 1,896,609 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| STATE STREET CORP | 2026-06-30 | 167,914 | 73,006 | 2.3 |
| CITADEL ADVISORS LLC | 2026-06-30 | 67,142 | 29,192 | 2.3 |
| Empowered Funds, LLC | 2026-06-30 | 136,958 | 59,547 | 2.3 |
| JANE STREET GROUP, LLC | 2026-06-30 | 26,394 | 11,476 | 2.2999 |
| JANE STREET GROUP, LLC | 2026-06-30 | 171,810 | 74,700 | 2.3 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD INDEX FUNDS | 2026-06-30 | Institutional Plus Shares | VEMPX | 200,182 | 460,418.6 | 0.0005 |
| VANGUARD INDEX FUNDS | 2026-06-30 | ETF Shares | VXF | 200,182 | 460,418.6 | 0.0005 |
| VANGUARD INDEX FUNDS | 2026-06-30 | Institutional Shares | VIEIX | 200,182 | 460,418.6 | 0.0005 |
| VANGUARD INDEX FUNDS | 2026-06-30 | Admiral Shares | VEXAX | 200,182 | 460,418.6 | 0.0005 |
| VANGUARD INDEX FUNDS | 2026-06-30 | Investor Shares | VEXMX | 200,182 | 460,418.6 | 0.0005 |